BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld
BioWorld
April 7, 2004
View Archived Issues
NPS Begins Teduglutide Pivotal Trial In Short-Bowel Syndrome
NPS Pharmaceuticals Inc. initiated a pivotal Phase III study for the orphan product teduglutide, a potential treatment for short-bowel syndrome. (BioWorld Today)
Read More
With $50M Series B, Archemix Has Funding To Last Until 2007
Read More
'Blockbuster Vs. Niche' Mindset Can Limit Profits, Skew Research
Read More
Australia-Based Norwood Seeks IPO On London's AIM Exchange
Read More
Xenogen Plans Sales Force Expansion With IPO Filing
Read More
Other News To Note
Read More